| Products | Business Development | News | Contact |
|
||
Overview
Nature uses the highly variable CDR-loops (Complementarity Determining Regions) in the variable domains of an antibody to form antigen binding sites. Modular Antibody Technology extends this principle to the non-CDR loops of constant as well as variable domains to engineer additional binding sites. Non-CDR loops are randomized, libraries of antibody fragments are created via standard techniques such as phage display and molecules with desired binding properties are selected from these libraries.
Modular Antibody Technology allows building additional functionality into therapeutic antibodies or antibody fragments of any size without changing the basic molecular structure of the respective starting molecule. Molecules that can be engineered include full antibodies (e.g. IgG), immunoglobulin constant regions (Fc), antigen binding fragments (Fab) and single chain antibodies (scFv) as well as diabodies, unibodies and single domain antibodies. Binding sites can be engineered against a broad range of therapeutically useful targets.
The technology is protected by a comprehensive IP portfolio owned by f-star, including a basic international patent application and a series of further applications claiming Modular Antibodies, libraries, products, methods and certain applications to develop product candidates.
Out of the broad range of potential applications, f-star currently focuses on two highly promising molecular formats: Fcab™ and mAb².